UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--Dec. 6, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 35 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the continued development of the Company's pipeline.
新泽西州普林斯顿--(业务通讯)--2024年12月6日--乌龙制药（纳斯达克：URGN），一家致力于开发和商业化创新解决方案以治疗尿路上皮癌和特殊癌症的生物科技公司，今天宣布向35名新员工授予诱导限制性股票单位（"RSUs"），与他们在乌龙制药的就业相关。这些新团队成员将支持Jelmyto（丝裂霉素）用于肾盂-肾盏溶液的持续商业化，乌龙制药的首个获批产品，以及公司的产品线的持续开发。
Up to 112,800 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee's continued service relationship with UroGen.
最多可发行112,800股乌龙制药的普通股，作为RSUs的归属和结算。RSUs将在三年内均匀归属，每年在归属日期的周年纪念日上归属三分之一的基础股份，前提是员工与乌龙制药的服务关系持续。
The RSUs are subject to the terms and conditions of UroGen's 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).
RSUs受乌龙制药2019年诱因计划以及根据该计划的RSU授予通知和协议的条款和条件的约束。这些RSUs是作为诱因授予给每一位与乌龙制药入职的员工，符合纳斯达克上市规则5635(c)(4)。
About UroGen Pharma Ltd.
关于乌龙制药有限公司
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey, with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma.
乌龙制药是一家致力于开发和商业化创新解决方案以治疗尿路上皮癌和特殊癌症的生物技术公司，因为患者应得更好的选择。乌龙制药开发了RTGel反向热水凝胶，这是一种专有的持续释放、基于水凝胶的平台技术，具有改善现有药物治疗特征的潜力。乌龙制药的持续释放技术旨在使尿道组织对药物的暴露时间更长，使局部治疗成为潜在更有效的治疗选择。乌龙制药的首个商业产品Jelmyto（美托咪啶）用于肾盂-肾盏溶液，以及针对低级别非肌肉侵袭性膀胱癌患者的实验性治疗UGN-102（美托咪啶）用于膀胱内注射，旨在通过非手术方式消融肿瘤。乌龙制药总部位于新泽西州普林斯顿，在以色列运营。访问以了解更多信息或在X（推特）上关注我们，@UroGenPharma。
Jelmyto, RTGel and UroGen are registered trademarks of UroGen Pharma Ltd.
Jelmyto、RTGel 和乌龙制药是乌龙制药有限公司的注册商标。
View source version on businesswire.com:
在businesswire.com上查看源版本：
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 ext. 1093
投资者联系方式：
文森特·佩罗尼
vincent.perrone@urogen.com
(609) 460-3588 分机 1093
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583 ext. 1083
媒体联系人：
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583 分机 1083
Source: UroGen Pharma Ltd.
来源：乌龙制药有限公司。
